Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 44Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 5Metastatic Castration-resistant Prostate Cancer 4Breast Neoplasms 4Prostate Carcinoma Metastatic to the Bone 2Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Hormone Refractory Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bone Metastatic Castration-resistant Prostate Cancer 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Pain 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Lung Neoplasms 1Fractures, Bone 1Fatigue 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasm Metastasis × radium Ra 223 dichloride × Clear all
NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
40 enrolled 18 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

Bayer

Phase 2 Completed
122 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01798108 2017-05-19

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Bayer

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Bayer

Phase 2 Completed
64 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00748046 2014-06-25

Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Bayer

Phase 1 Completed
10 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡